Your session is about to expire
← Back to Search
Metformin for Aging (ANTHEM Trial)
ANTHEM Trial Summary
This trial is testing whether the drug metformin can help slow aging by improving insulin sensitivity and regulating glucose in the body. They will be testing this on 148 people, half of which will take metformin and half a placebo, over the course of 12 weeks.
ANTHEM Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowANTHEM Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 4 trial • 156 Patients • NCT02002221ANTHEM Trial Design
Find a Location
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Does this research project allow people who are 60 or older to participate?
"The team is currently looking for participants who fall in the age range of 40 to 75 years old."
Why is Metformin a popular choice among doctors?
"Metformin is most frequently used to treat type 2 diabetes, but it can also be effective in managing diabetic ketoacidosis, polycystic ovary syndrome, and other conditions."
Can you tell us about other times Metformin has been used in research?
"There are one hundred and eighty (180) ongoing studies into Metformin. Forty-five (45) of those are in Phase 3. Most research teams for Metformin are based in Rockville, Maryland; however, there 1952 total locations running trials for this medication."
Are we still able to welcome new participants into this research project?
"That is correct, the online clinicaltrials.gov registry reveals that this study is still ongoing and looking for participants. The first posting was on 29 July 2020 with the most recent edit taking place 16 November 2021. A total of 148 patients will be recruited from 2 sites."
Are there specific characteristics that make a person eligible for this clinical trial?
"This trial is seeking 148 patients that are between 40 and 75 years old. To be eligible, potential participants must also have insulin resistance and meet the following additional requirements: comprehension of the protocol as indicated by an ability to respond to questions about the study after reading the consent form; ability to use and be contacted by telephone; ability to speak, read, and understand English; independently mobile."
Has Metformin been cleared by the FDA?
"Metformin has been studied enough to support its efficacy, and there is also data that suggests it is safe for use. Therefore, we gave it a score of 3."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Average response time
- < 2 Days
Most responsive sites:
- University of Oklahoma Health Sciences Center, Oklahoma Shared Clinical and Translational Resources: < 24 hours
Share this study with friends
Copy Link
Messenger